Ajinomoto Co., Ltd.

Japan Science and Technology Corporation

Research Development Corporation of Japan

Kunio Torii

Hisayuki Uneyama

Takami Maekawa

Ana San Gabriel

Hiroyuki Kojima

Kiyoshi Miwa

Shinichi Fujita

Masaru Okutsu

Takaaki Kobayashi

Kahei Takase

Yutaka Oomura

Takashi Meguro

Masabumi Yasunami

Tatsuro Tanaka

Tomio Suda

Toru Mimura

Akira Shinji

Hisanori Masaki

Takashi Kondo

Hrudananda Mallick

Takashi Yokawa

Kazuo Sasaki

Tatsuro Ajinomoto Co Inc Tanaka

Hisayuki Ajinomoto Co Inc Uneyama

As a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which improve lower gastrointestinal function and are effective for the prophylaxis or improvement of diarrhea, gastroesophageal reflux or misswallowing caused by administration of a liquid nutritional supplement, the present invention provides a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which comprise at least one kind selected from glutamic acid, 5'-nucleotide and a salt thereof, wherein, when glutamic acid alone is contained, the content thereof on administration is 0.0013-1.3 w/v % as free glutamic acid.

Nutrient composition and composition for prevention/mitigation of digestive tract depression

An isolated DNA molecule which encodes a novel glutamate receptor and a transformed cell expressing the receptor are provided.

Glutamate receptors and utilization thereof

The inventive subject matter relates to a glutamate receptor, DNA which encodes the receptor, a transformed cell expressing the receptor, a method for producing the receptor, a method for identifying an agonist, antagonist, or allosteric modulator for glutamic acid, a method for identifying an agonist for glutamic acid, an antibody to the receptor, and processes for making glutamate receptor modulators and pharmaceutical compositions comprising said modulator.

Glutamate receptor and utilization thereof

An agonist or antagonist of glutamic acid or an allosteric modulator is screened by reacting a glutamic acid receptor protein having the following properties with a substance binding thereto in the presence of a test substance and detecting the inhibition or promotion of the reaction: (A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, or (B) it has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.

Glutamic acid receptor and utilization thereof

The present invention provides an activity-inhibitor for glutamic acid in the brain which comprises L-lysine or its derivatives. The present invention also provides an activity-inhibitor for glutamic acid in the brain which comprises L-arginine or its derivatives. The present invention further provides an activity-potentiator for glutamic acid in the brain which comprises glycine or its derivatives.

Activity-inhibitor and activity-potentiator for glutamic acid in the

A method of magnetic resonance imaging of cerebral blood flow uses a pulse sequence of a rapid gradient-echo method, wherein the pulse is an RF pulse having a slice gradient, a read gradient and a phase-encode gradient. The RF pulse is provided with a flip angle of between 45 and 60 degrees, and an additional gradient is added to each of the slice gradient, read gradient and phase-encode gradient, thereby diffusing and refusing proton spin in the cerebral blood flow. Very slight changes in the blood flow in the brain can be imaged and diabetes can be diagnosed by detecting the increase in the blood flow in a specific brain region after systemic administration of insulin.

Magnetic resonance imaging of cerebral blood flow and diagnosis of

A subject suffering from ischemic shock is treated by administering to the subject a therapeutically effective amount of aFGF as the active ingredient of a pharmaceutical composition further containing a pharmaceutically acceptable carrier.

Drug for the treatment of senile dementia of the ischemic and

A composition, comprising L-alanine or a salt thereof, L-glutamine or a salt thereof, and an oligopeptide containing either a L-alanine residue or a L-glutamine residue, or both, is disclosed. A composition made up of (i) L-alanine or a salt thereof, (ii) L-glutamine or a salt thereof, and (iii) an oligopeptide containing a L-alanine or a L-glutamine residue is also discloed. The L-alanine and the L-glutamine are present in these compositions in an available molar ratio of from 1:0.1 to 1:10, respectively. These compositions are useful in the therapy or prevention of hepatic disorders.

Compositions useful for the treatment and/or prevention of hepatic

An azulene derivative capable of exerting a hypocholesterolemic effect on a mammal which is represented by the formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 alkyl groups and C.sub.2 -C.sub.12 alkenyl groups.

Azulene derivatives and their use as hypocholesterolemics

Growing community of inventors

Kawasaki, Japan

Kunio Torii